FIA
PHAS

FNY Investment Advisers’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

FNY Investment Advisers’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$61K – 921
2019
Q4 		$61K Buy
+10,000
New +$41.2K 0.02% 444

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FNY Investment Advisers's PHAS Position: Q1 2020 in Review

FNY Investment Advisers sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2020, closing a stake of 10,000 shares — an estimated $61K sold.

FNY Investment Advisers first reported a position in PHAS in Q4 2019 and held it in 1 quarter. The position peaked at $61K in Q4 2019. 50 funds tracked by Wall St. Rank hold PHAS as of Q1 2020.

  • FNY Investment Advisers reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 10,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $61K.
  • FNY Investment Advisers first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • FNY Investment Advisers's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $61K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on FNY Investment Advisers's 13F filing for Q1 2020, filed 9 Apr 2020.